U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07298148) titled 'Double-Dose Firmonertinib in EGFR-Mutant Advanced NSCLC Achieving Stable Disease After Standard-Dose First-Line Firmonertinib' on Dec. 11.
Brief Summary: This study evaluates the efficacy and safety of Firmonertinib 160 mg once daily in patients with EGFR-mutant, advanced NSCLC who achieve stable disease after first-line Firmonertinib 80 mg for 8 weeks.
Study Start Date: Jan. 01, 2026
Study Type: INTERVENTIONAL
Condition:
NSCLC Stage IV
EGFR Positive Non-small Cell Lung Cancer
EGFR-TKI Sensitizing Mutation
Intervention:
DRUG: Firmonertinib 160mg
Patients enter an 8-week induction phase at 80 mg once daily. Those with stable d...